15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $12.0B | $4.0B | 86.2% | 34.8% | $3.2B | — | $5.1B |
| 2024 | $11.0B | -$536M | 86.1% | -2.1% | -$790M | — | $4.6B |
| 2023 | $9.9B | $3.6B | 87.2% | 38.8% | $3.3B | — | $10.4B |
| 2022 | $8.9B | $3.3B | 87.9% | 48.2% | $3.9B | — | $10.5B |
| 2021 | $7.6B | $2.3B | 88.1% | 36.7% | $2.4B | — | $6.8B |
| 2020 | $6.2B | $2.7B | 88.1% | 46.0% | $3.0B | — | $6.0B |
| 2019 | $4.2B | $1.2B | 86.8% | 28.8% | $1.5B | — | $3.1B |
| 2018 | $3.0B | $2.1B | 86.6% | 20.8% | $1.2B | — | $2.7B |
| 2017 | $2.5B | $263M | 88.9% | 5.0% | $746M | — | $1.7B |
| 2016 | $1.7B | -$112M | 87.6% | 0.6% | $180M | — | $1.2B |
| 2015 | — | -$556M | — | — | -$411M | — | $715M |
| 2014 | — | -$739M | — | — | -$624M | — | $625M |
| 2013 | — | -$445M | — | — | -$112M | — | $569M |
| 2012 | — | -$107M | — | — | $197M | — | $489M |
| 2011 | — | $30M | — | — | $109M | — | $475M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3.0B | $1.0B | 86.8% | 38.1% | $1.3B | — | $5.5B |
| Dec '25 | $3.2B | $1.2B | 85.4% | 37.8% | $349M | — | $5.1B |
| Sep '25 | $3.1B | $1.1B | 86.5% | 38.6% | $1.1B | — | $4.9B |
| Jun '25 | $3.0B | $1.0B | 86.3% | 38.8% | $927M | — | $5.0B |
| Mar '25 | $2.8B | $646M | 86.9% | 22.7% | $778M | — | $4.7B |
| Dec '24 | $2.9B | $913M | 85.5% | 35.2% | $492M | — | $4.6B |
| Sep '24 | $2.8B | $1.0B | 85.8% | 40.3% | $1.3B | — | $5.2B |
| Jun '24 | $2.6B | -$3.6B | 85.9% | -132.9% | -$3.8B | — | $4.6B |
| Mar '24 | $2.7B | $1.1B | 87.3% | 42.4% | $1.2B | — | $9.2B |
| Dec '23 | $2.5B | $969M | 85.4% | 39.3% | $177M | — | $10.4B |
| Sep '23 | $2.5B | $1.0B | 87.2% | 41.8% | $1.2B | — | $11.1B |
| Jun '23 | $2.5B | $916M | 87.6% | 41.2% | $1.1B | — | $10.2B |
| Mar '23 | $2.4B | $700M | 88.8% | 32.8% | $858M | — | $9.3B |
| Dec '22 | $2.3B | $819M | 87.7% | 44.9% | $1.0B | — | $10.5B |
| Sep '22 | $2.3B | $931M | 87.6% | 48.3% | $901M | — | $9.2B |
| Jun '22 | $2.2B | $811M | 88.1% | 50.4% | $1.1B | — | $8.7B |
| Mar '22 | $2.1B | $762M | 88.3% | 49.6% | $893M | — | $7.6B |
| Dec '21 | $2.1B | $770M | 88.1% | 42.3% | $933M | — | $6.8B |
| Sep '21 | $2.0B | $852M | 88.1% | 53.1% | $875M | — | $6.3B |
| Jun '21 | $1.8B | $67M | 87.3% | -2.1% | -$250M | — | $6.1B |
How the market has priced VRTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Vertex Pharmaceuticals's revenue has grown 14.1% per year, and net income grown 7.8% per year. These are computed facts, not advice.
As of FY2025, Vertex Pharmaceuticals reported — of total debt against $5.1B of cash; operating income covered interest expense 314×.
In FY2025, gross margin was 86.2%, operating margin 34.8%, and net margin 32.9%.
As of Jun '26, Vertex Pharmaceuticals traded at a price-to-earnings ratio of about 30.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.